]>
IRCT20170814035697N5 IRCT 2019-12-16 Oroumia University of Medical Sciences Evaluation of the effect of silymarin on blood sugar profile(FBSand 2hpp ) and HbA1C in patients with type 2 diabetes mellitus UGS Evaluation of the effect of silymarin on blood sugar profile(FBSand 2hpp ) and HbA1C in patients with type 2 diabetes mellitus 2019-04-06 anticipated 50 Complete https://irct.ir/trial/38237 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The randomization method is that 50 letters A and 50 B characters are poured into a bag, and if a sample is chosen, a number is randomly taken out of the bag. If the letter A is the group receiving the silymarin, and if the letter B The control group was identified, Blinding description: In this study, the patient, the person who performed the project, the relevant guidance teachers, and the patient's blind physician were kept so that none of them is aware of the type of drug (silymarin or placebo) by the patient. 1-2 Blood glucose profiles in patients with type 2 diabetes. Intervention 1: Intervention group: routin treatment +livergol tablets with a dose of 140 mg ,BID ,daily for patients with type 2 DM. Intervention 2: Control group: routin anti diabetes treatment with placebo. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is My decision to publish is related to the views of other projects partners.
public Hamdolah Sharifi
Department of Pharmacology, Faculty of Pharmacy, Urmia University of Medical Sciences, Urmia
Urmia Iran (Islamic Republic of) 5714783734 +98 44 3275 4992 sharifi.h@umsu.ac.ir Urmia University of Medical Sciences scientific Dr. Hamdolah Sharifi
Department of Pharmacology, Faculty of Pharmacy, Urmia University of Medical Sciences, Urmia
Urmia Iran (Islamic Republic of) 5714783734 +98 44 3275 4992 sharifi.h@umsu.ac.ir Oroumia University of Medical Sciences Iran (Islamic Republic of) age between 30-65 diagnose of diabetics according to WHO criteria FBS>126mg/dl or 2HP>200mg/dl or HbA1c>9% fasting blood glucose less thanmg/dL 250 A history of diabetes is more than 1 year old Conscious informed consent to participate in the study 30 years 65 years Both Insulin therapy Pregnancy and lactation catching for autoimmune diseases and cancer Taking drugs that interfere with the level of plasma glucose smoking Hospitalized or undergoing surgery R73 Elevated blood glucose level Treatment - Drugs Treatment - Drugs Intervention group: routin treatment +livergol tablets with a dose of 140 mg ,BID ,daily for patients with type 2 DM Control group: routin anti diabetes treatment with placebo Blood glucose profiles. Timepoint: Before and after of treatment. Method of measurement: Lab data. Urmia University of Medical Sciences Approved 2018-12-12 Ethics committee of Urmia University of Medical Sciences Urmia University of Medical Sciences;Resalat Ave;Jahad Blvd;Urmia;West Azerbijan Provine;Iran urmia West Azarbaijan Iran (Islamic Republic of)